To determine the kidney function in patients before and after enhanced external counterpulsation treatment
- Conditions
- Ischaemic heart disease, chronic stable angina, chronic stable heart failureCirculatory System
- Registration Number
- ISRCTN11560035
- Lead Sponsor
- Piyavate Hospital (Thailand)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 26
1. Both males and females, age >18 years
2. Patients with refractory angina, chronic stable angina or chronic stable heart failure
3. Willing to participate in the study with informed consent
1. Patient with the diagnosis of congestive heart failure within 1 month prior to study entry
2. Patient with the diagnosis of acute coronary syndrome within 1 month prior to study entry
3. Patient with uncontrolled blood pressure (>180/110 mmHg)
4. Patient with cardiac arrhythmia (e.g. atrial fibrillation or atrial flutter or frequent premature ventricular contractions) that may interfere with triggering of EECP system
5. Patients with severe lower extremity vaso-occlusive disease
6. Patients with end stage renal disease requiring renal replacement therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum cystatin C<br><br>All primary and secondary outcome measures will be assessed before and within 1 month, and 5-7 months after completion of EECP treatment of 35 sessions.
- Secondary Outcome Measures
Name Time Method 1. Calculated glomerular filtration rate (GFR) <br>2. Serum N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) <br>3. Ejection fraction determined by echocardiography <br><br>All primary and secondary outcome measures will be assessed before and within 1 month, and 5-7 months after completion of EECP treatment of 35 sessions.